StageZero Life Sciences Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SZLSF research report →
Companywww.stagezerolifesciences.com
StageZero Life Sciences Ltd. , a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood.
- CEO
- James R. Howard-Tripp
- IPO
- 2009
- Employees
- 40
- HQ
- Richmond Hill, ON, CA
Price Chart
Valuation
- Market Cap
- $630.02K
- P/E
- -0.04
- P/S
- 0.17
- P/B
- -0.07
- EV/EBITDA
- -0.24
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -10.64%
- Op Margin
- -204.13%
- Net Margin
- -300.79%
- ROE
- 481.50%
- ROIC
- 151.84%
Growth & Income
- Revenue
- $3.80M · -25.12%
- Net Income
- $-11,415,372 · -52.53%
- EPS
- $-0.11 · -10.00%
- Op Income
- $-7,746,761
- FCF YoY
- 61.24%
Performance & Tape
- 52W High
- $0.03
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.30
- Avg Volume
- 17
Get TickerSpark's AI analysis on SZLSF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SZLSF Coverage
We haven't published any research on SZLSF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SZLSF Report →